… At present, there have been several cost-effectiveness studies comparing … the cost-effectiveness
of all the 5 oral anticoagulants (OACs) available in the US market for stroke prophylaxis …

… Ischemic stroke and ICH were further divided with respect to disease severity. Clinically
relevant non-major bleeding referred to the non-major bleeding that required hospitalization. …

… ischemic stroke. The purpose of this study was to assess the cost-effectiveness of anticoagulation
in … ) who have a higher incidence of bleeding events while undergoing anticoagulation. …

Full article: Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke
prevention in non-valvular atrial fibrillation: a systematic and qualitative review Skip to Main …

… use in non-valvular atrial fibrillation. Patients enter the model … as ischemic stroke (fatal,
major, minor, or transient ischemic … the cost-effectiveness data for the novel oral anticoagulants …

… It illustrates that all patients start at 65 years old with non-valvular atrial fibrillation (NVAF) …
the odds ratio for ischemic stroke between the different oral anticoagulants. Dabigatran means …

… anticoagulation treatment for nonvalvular atrial fibrillation(NVAF). The objective of this study
was to evaluate the cost effectiveness … health states: NVAF, ischemic stroke (mild, moderate, …

… the new direct oral anticoagulants, used dose-adjusted warfarin as standard of control and
showed noninferiority or superiority for the efficacy outcome of ischemic stroke and systemic …

… oral anticoagulant/s for prevention of stroke in AF and for primary prevention, treatment and
secondary prevention … 60 FIGURE 10 Network plot for ischaemic stroke (stroke prevention in …

… The consequences of AF included in the model were ischaemic stroke, intracranial haemorrhage,
… Incremental cost-effectiveness ratios and cost-effectiveness acceptability curves were …